Alnylam Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ALNY Nasdaq 2830 www.alnylam.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alnylam Pharmaceuticals, Inc.

Exploring 3 High Growth Tech Stocks in the US Market - Jun 20th, 2025 5:38 am
Exploring Three High Growth Tech Stocks In The US Market - Jun 19th, 2025 11:38 am
Alnylam Pharmaceuticals (NasdaqGS:ALNY) Appoints New R&D Chief to Drive Growth Phase - Jun 19th, 2025 11:36 am
Alnylam names Pushkal Garg as EVP, chief research and development officer - Jun 19th, 2025 8:10 am
Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer - Jun 18th, 2025 8:05 am
Exploring High Growth Tech Opportunities in US Markets - Jun 17th, 2025 5:38 am
Exploring High Growth Tech Stocks In The US This June 2025 - Jun 16th, 2025 5:47 am
The European Commission Approves Alnylam’s AMVUTTRA - Jun 11th, 2025 5:31 pm
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program - Jun 11th, 2025 5:00 am
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM - Jun 10th, 2025 7:08 am
EC approves Alnylam’s vutrisiran for ATTR-CM treatment - Jun 10th, 2025 3:21 am
Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy - Jun 9th, 2025 4:00 am
Why Is Sarepta Therapeutics (SRPT) Up 7.7% Since Last Earnings Report? - Jun 5th, 2025 9:31 am
Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference - May 28th, 2025 6:00 am
3 High-Flying Stocks That Could Soar Even More - May 24th, 2025 4:40 am
Alnylam Issues 2024 Corporate Responsibility Report - May 20th, 2025 7:00 am
AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B - May 17th, 2025 3:50 am
High Growth US Tech Stocks To Watch In May 2025 - May 16th, 2025 5:45 am
Alnylam Pharmaceuticals, Inc. (ALNY): Among the Best Growth Stocks to Buy and Hold for the Long Term - May 13th, 2025 8:18 pm
Alnylam Pharmaceuticals (NasdaqGS:ALNY) To Present Pivotal TTR Franchise Data At Heart Failure Congress - May 12th, 2025 11:20 am